Protocol Ledger

NCT04093024 · Phase III · COMPLETED

A Study to Find Out How Nintedanib is Taken up in the Body and How Well it is Tolerated in Children and Adolescents With Interstitial Lung Disease (ILD)

Interventional Phase III clinical trial protocol NCT04093024 sponsored by Boehringer Ingelheim in Respiratory and Pulmonary, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2019-12-03 Enrollment: 39 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT04093024
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)39 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04093024
Protocol FieldVerified Registry Value
NCT IdentifierNCT04093024
Consolidated Lead SponsorBoehringer Ingelheim
Therapeutic Condition CohortRespiratory and Pulmonary
Clinical Trial PhasePhase III
Overall Recruitment StatusCOMPLETED
Registered Enrollment39 participants (ACTUAL)
Registered Start Date2019-12-03
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT04093024
Hospital Research SiteLocationSite Profile
Children's Hospital Los AngelesLos Angeles, CAOpen Hospital Dossier ->
Children's Hospital ColoradoAurora, COOpen Hospital Dossier ->
Children's Mercy Hospitals and ClinicsKansas City, MOOpen Hospital Dossier ->
Weill Cornell MedicineNew York, NYOpen Hospital Dossier ->

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Boehringer Ingelheim across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Respiratory and Pulmonary Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI